David H. Deming, a director at Phio Pharmaceuticals Corp., recently reported acquiring 12,000 shares of the company's common stock over two days. This activity, filed on November 16, 2026, is significant as it reflects Deming's confidence in the company's future prospects.

Deming's transactions took place on November 12 and November 13, where he purchased 9,000 shares at $0.8136 each and 3,000 shares at $0.8334 each. Following these transactions, he now owns a total of 61,800 shares of Phio Pharmaceuticals Corp.

Background

Phio Pharmaceuticals Corp. is a company based in King of Prussia, Pennsylvania, focused on pharmaceutical preparations. The company operates under the SIC code 2834, which pertains to the pharmaceutical preparations industry. Recent filings indicate that Phio Pharmaceuticals has been active in the market, with Deming's recent transactions adding to the narrative of the company's ongoing developments.

What the Filing Says

The filing details that Deming acquired 9,000 shares on November 12 and 3,000 shares on November 13. The filing states, "Includes shares of common stock underlying unvested restricted stock units." This indicates that part of Deming's ownership may come from stock units that are yet to vest.

Impact

Deming's stock purchases may influence other shareholders and potential investors, signaling confidence in Phio Pharmaceuticals' trajectory. As a director, his actions could also impact the company's stock performance and investor sentiment within the pharmaceutical sector.

What's Next

The filing does not say what happens next.